Eli Lilly and Company (NYSE:LLY) CAO Sells $2,370,020.00 in Stock

Eli Lilly and Company (NYSE:LLY) CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Price Performance

LLY stock traded down $18.98 during trading on Tuesday, hitting $1,212.96. The stock had a trading volume of 2,087,659 shares, compared to its average volume of 3,136,508. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a twelve month low of $629.40 and a twelve month high of $1,249.45. The stock has a market capitalization of $1.14 trillion, a P/E ratio of 40.70, a PEG ratio of 1.38 and a beta of 0.51. The company’s 50-day moving average price is $1,162.38 and its two-hundred day moving average price is $1,048.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts predict that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on LLY shares. Morgan Stanley reaffirmed an “overweight” rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. Royal Bank Of Canada boosted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Barclays upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, Truist Financial raised their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently modified their holdings of the company. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $30,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the period. New England Capital Financial Advisors LLC lifted its holdings in Eli Lilly and Company by 142.9% in the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the last quarter. Finally, Maseco LLP lifted its holdings in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. This is the pill’s first regulatory approval outside the United States and gives Lilly access to a major European market. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: The approval expands Lilly’s obesity portfolio beyond injectable medicines and could improve patient convenience and market adoption. Foundayo will initially be available through private prescriptions, while potential access through Britain’s National Health Service depends on a cost-effectiveness review. Lilly Takes Its Weight-Loss Pill Battle Overseas
• Positive Sentiment: Investor sentiment remains supported by Lilly’s strong recent results: quarterly revenue increased 47.7% year over year to $22.97 billion, while earnings per share of $8.38 exceeded the $6.40 consensus estimate. Management raised fiscal 2026 EPS guidance to $35.50–$36.50, marking another outlook increase. Eli Lilly Beat Big and Raised Guidance
• Neutral Sentiment: Analysts have lifted some valuation targets, with one updated fair-value estimate rising to $1,297.31. However, the stock is trading near its 52-week high and at roughly 41 times earnings, leaving less room for disappointment. Eli Lilly Fair Value Bump
• Negative Sentiment: Erste Group Bank lowered its fiscal 2026 EPS estimate to $34.93 from $35.34. Although the revised forecast remains close to Lilly’s guidance, the cut contrasts with the broader bullish outlook. Eli Lilly analyst estimate
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The scheduled nature of the transaction makes it a limited bearish signal, but it may add some selling pressure. SEC Form 4 Filing

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.